Tech For Licensing

Technology Content


Ref No: B05059
Research Institute : IBN

Technology Overview

Hyaluronic acid (HA) is a non sulphated glycosaminoglycan found in the extracellular matrix (ECM). It forms a viscoelastic mesh that is capable of retaining water and thereby maintaining tissue volume. It is the major constituent in the vitreous humor and synovial fluid, and is used in the various medical and cosmetic application. However, in its free form, HA is rapidly degraded. Here we offer a solution to overcome this challenge. 

Our Innovation

Dr Kurisawa and his team specialize in drug delivery systems. They invented a Hyaluronic acid –  Epigallocatechin-3-gallate (HA-EGCG) conjugate. Furthermore, they demonstrated to form the hydrogels via the oxidative coupling of EGCG moiety. The advantages of this system are


  • Possess bioactivities such as resistance to hyaluronidase-mediated degradation, inhibition of cell growth and scavenging of radicals, whereas unmodified HA shows no or limited activities. 
  • The HA-EGCG hydrogel system, with in situ gelation and resistance toward hyaluronidase-mediated degradation, offers the advantages of injectability and prolonged residence time in the body.


Our results showed these hydrogels have resistance towards enzymatic degradation by hyaluronidase.

Potential Applications

  • Cosmetic application including dermal filler
  • Viscoelastic material for ophthalmological surgery to prevent collapse of the anterior chamber
  • Viscosupplements such as for osteoarthritis treatment; restore viscoelasticity in arthritic joints
  • Sustained release drug delivery system

Our Value Proposition

Our in vivo test showed very positive results. The team are competent and confident to establish commercial collaboration  in


  • Joint-development of the various application utilizing the unique feature of this technology.
  • Transferring of our expertise in licensing partnership. 

Categories : Materials and Chemicals - Biomedical , Materials and Chemicals - Fine Chemicals, Medical Devices - Surgery, Pharmaceuticals - Therapeutics , Pharmaceuticals - Drug Delivery , Life Sciences - Others
Intellectual Property : Publication Ready,Patent - Pending,Patent - Granted
Technology Development Status : Concept,POC
Tags : 5059, 5656, 7960, 8380, Hyaluronic acid, HA, Epigallocatechin-3-gallate, EGCG, HA-EGCG, dermal filler, viscoelastic material, ophtalmological, viscosuppplement, osteoarthritis, hydrogel, personal care, hyaluronidase, radical scavenging

HA EGCG 1.jpg

Users who read this article also read: